P3 Health Partners (PIII) EBIAT (2020 - 2025)
P3 Health Partners (PIII) has disclosed EBIAT for 6 consecutive years, with -$69.5 million as the latest value for Q3 2025.
- For the quarter ending Q3 2025, EBIAT fell 49.34% year-over-year to -$69.5 million, compared with a TTM value of -$216.0 million through Sep 2025, down 74.15%, and an annual FY2024 reading of -$135.8 million, down 135.14% over the prior year.
- EBIAT was -$69.5 million for Q3 2025 at P3 Health Partners, down from -$43.7 million in the prior quarter.
- Across five years, EBIAT topped out at $759.1 million in Q4 2022 and bottomed at -$154.3 million in Q2 2022.
- Average EBIAT over 5 years is -$7.2 million, with a median of -$40.5 million recorded in 2023.
- The sharpest move saw EBIAT plummeted 423.85% in 2022, then soared 84.87% in 2023.
- Year by year, EBIAT stood at -$145.5 million in 2021, then soared by 621.55% to $759.1 million in 2022, then tumbled by 104.91% to -$37.3 million in 2023, then plummeted by 57.2% to -$58.6 million in 2024, then fell by 18.5% to -$69.5 million in 2025.
- Business Quant data shows EBIAT for PIII at -$69.5 million in Q3 2025, -$43.7 million in Q2 2025, and -$44.2 million in Q1 2025.